BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
6 Web-based Lawful Administrations: Extensive Surveys and Elements- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- Lucky airplane passengers capture NASA's Artemis 2 moon launch from the sky
- Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
- Must-See Attractions in Washington, D.C.
- The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- Turning into a Sharp Financial backer: Individual budget Wins
- How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia
- Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
